Ségolène Aymé
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ségolène Aymé has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Béatrice Godard
INSERM SC11, Paris, France
4 shared publicationsOn Behalf Of The European Society Of Human Genetics' Pppc
4 shared publications- Gert Matthijs
Laboratory for Molecular Diagnosis, Center for Human Genetics, KU Leuven, Leuven, Belgium
3 shared publications - Sirpa Soini
National Institute for Health and Welfare (THL), Helsinki, Finland
2 shared publications Anna Kole
1 shared publication- Bruno Dallapiccola
Genetics and Rare Disease Research Division, Bambino Gesù Children Hospital, IRCCS, 00146 Rome, Italy
1 shared publication
Latest Publications
- 1 June 2008
- Published by Elsevier in The Lancet
- Vol. 371 (9629) , 2048-2051
Empowerment of patients: lessons from the rare diseases community
- 1 June 2008
- Published by Elsevier in The Lancet
- Vol. 371 (9629) , 2048-2051
Empowerment of patients: lessons from the rare diseases community
- 24 April 2008
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 16 (S1) , S10-S50
Patenting and licensing in genetic testing: ethical, legal and social issues
Patents for inventions can be beneficial for society, if they drive innovation and promote progress. In most areas, the patenting system works satisfactorily. However, it must be recognized that in some instances it can also be problematic; this is the case in the field of genetics, and particularly in the area of genetic testing. As patents should serve their original purpose (promoting innovation through a fair reward system for the inventors), the European Society of Human Genetics (ESHG) suggests ways to improve the mechanisms that already form part of the patents system as a whole. In brief, the ESHG recommends limiting the breadth of the claims in genetic patents and, more practically, to reduce the number of patents by limiting the patentable subject matter, thereby improving the quality of the patents that will eventually be granted. There is also a suggestion to redefine the concept of utility in patent law, by taking account of downstream clinical experience. The ESHG sees no harm in the patenting of novel technical tools for genetic testing (eg PCR or chip technologies), as they can promote investment and still allow for invention around them. Many disputes between supporters of the patenting system and the public revolve around ethical issues. The European Patent Office should consider the benefit of having an ethics committee to consider issues of major interest, such as patents applied to genes. The problem of licensing should also be addressed. Practically, this means supporting the Organisation for Economic Co-operation and Development guidelines, which prescribe that licences should be non-exclusive and easily obtainable, both in practical and in financial terms. To promote this, the practical exploration of alternative models for licensing, like patent pools and clearinghouses, is a prerequisite. To better track developments in this field, the establishment of a voluntary reporting system, whereby geneticists could report on any issues related to new and/or old patents or licences in the light of service provision to patients, would be worthwhile. Finally, the ESHG is calling upon all stakeholders to start the process of developing a code of conduct for partners with patents, covering ethical aspects as well as smooth licensing arrangements.
- 24 April 2008
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 16 (S1) , S10-S50
Patenting and licensing in genetic testing: ethical, legal and social issues
Patents for inventions can be beneficial for society, if they drive innovation and promote progress. In most areas, the patenting system works satisfactorily. However, it must be recognized that in some instances it can also be problematic; this is the case in the field of genetics, and particularly in the area of genetic testing. As patents should serve their original purpose (promoting innovation through a fair reward system for the inventors), the European Society of Human Genetics (ESHG) suggests ways to improve the mechanisms that already form part of the patents system as a whole. In brief, the ESHG recommends limiting the breadth of the claims in genetic patents and, more practically, to reduce the number of patents by limiting the patentable subject matter, thereby improving the quality of the patents that will eventually be granted. There is also a suggestion to redefine the concept of utility in patent law, by taking account of downstream clinical experience. The ESHG sees no harm in the patenting of novel technical tools for genetic testing (eg PCR or chip technologies), as they can promote investment and still allow for invention around them. Many disputes between supporters of the patenting system and the public revolve around ethical issues. The European Patent Office should consider the benefit of having an ethics committee to consider issues of major interest, such as patents applied to genes. The problem of licensing should also be addressed. Practically, this means supporting the Organisation for Economic Co-operation and Development guidelines, which prescribe that licences should be non-exclusive and easily obtainable, both in practical and in financial terms. To promote this, the practical exploration of alternative models for licensing, like patent pools and clearinghouses, is a prerequisite. To better track developments in this field, the establishment of a voluntary reporting system, whereby geneticists could report on any issues related to new and/or old patents or licences in the light of service provision to patients, would be worthwhile. Finally, the ESHG is calling upon all stakeholders to start the process of developing a code of conduct for partners with patents, covering ethical aspects as well as smooth licensing arrangements.
- 24 April 2008
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 16 (S1) , S1-S2
Introduction
- 24 April 2008
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 16 (S1) , S1-S2
Introduction
- 20 March 2008
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 16 (4) , 405-411
Patenting and licensing in genetic testing
Patents for inventions can be beneficial for society, if they drive innovation and promote progress. In most areas, the patenting system works satisfactorily. However, it must be recognized that in some instances it can also be problematic; this is the case in the field of genetics, and particularly in the area of genetic testing. As patents should serve their original purpose (promoting innovation through a fair reward system for the inventors), the European Society of Human Genetics (ESHG) suggests ways to improve the mechanisms that already form part of the patents system as a whole. In brief, the ESHG recommends limiting the breadth of the claims in genetic patents and, more practically, to reduce the number of patents by limiting the patentable subject matter, thereby improving the quality of the patents that will eventually be granted. There is also a suggestion to redefine the concept of utility in patent law, by taking account of downstream clinical experience. The ESHG sees no harm in the patenting of novel technical tools for genetic testing (eg PCR or chip technologies), as they can promote investment and still allow for invention around them. Many disputes between supporters of the patenting system and the public revolve around ethical issues. The European Patent Office should consider the benefit of having an ethics committee to consider issues of major interest, such as patents applied to genes. The problem of licensing should also be addressed. Practically, this means supporting the Organisation for Economic Co-operation and Development guidelines, which prescribe that licenses should be non-exclusive and easily obtainable, both in practical and in financial terms. To promote this, the practical exploration of alternative models for licensing, like patent pools and clearinghouses, is a prerequisite. To better track developments in this field, the establishment of a voluntary reporting system, whereby geneticists could report on any issues related to new and/or old patents or licenses in the light of service provision to patients, would be worthwhile. Finally, the ESHG is calling upon all stakeholders to start the process of developing a code of conduct for partners with patents, covering ethical aspects as well as smooth licensing arrangements.status: publishe
- 20 March 2008
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 16 (4) , 405-411
Patenting and licensing in genetic testing
Patents for inventions can be beneficial for society, if they drive innovation and promote progress. In most areas, the patenting system works satisfactorily. However, it must be recognized that in some instances it can also be problematic; this is the case in the field of genetics, and particularly in the area of genetic testing. As patents should serve their original purpose (promoting innovation through a fair reward system for the inventors), the European Society of Human Genetics (ESHG) suggests ways to improve the mechanisms that already form part of the patents system as a whole. In brief, the ESHG recommends limiting the breadth of the claims in genetic patents and, more practically, to reduce the number of patents by limiting the patentable subject matter, thereby improving the quality of the patents that will eventually be granted. There is also a suggestion to redefine the concept of utility in patent law, by taking account of downstream clinical experience. The ESHG sees no harm in the patenting of novel technical tools for genetic testing (eg PCR or chip technologies), as they can promote investment and still allow for invention around them. Many disputes between supporters of the patenting system and the public revolve around ethical issues. The European Patent Office should consider the benefit of having an ethics committee to consider issues of major interest, such as patents applied to genes. The problem of licensing should also be addressed. Practically, this means supporting the Organisation for Economic Co-operation and Development guidelines, which prescribe that licenses should be non-exclusive and easily obtainable, both in practical and in financial terms. To promote this, the practical exploration of alternative models for licensing, like patent pools and clearinghouses, is a prerequisite. To better track developments in this field, the establishment of a voluntary reporting system, whereby geneticists could report on any issues related to new and/or old patents or licenses in the light of service provision to patients, would be worthwhile. Finally, the ESHG is calling upon all stakeholders to start the process of developing a code of conduct for partners with patents, covering ethical aspects as well as smooth licensing arrangements.status: publishe
- 19 November 2007
- Published by Springer Nature in Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
- Vol. 50 (12) , 1477-1483
Networking for rare diseases: a necessity for Europe
Most rare diseases are life-threatening and chronically debilitating conditions, and the vast majority of them are genetically determined. Their individually low prevalence requires special combined efforts to address them so as to improve diagnosis, care and prevention. Though it is difficult to develop a public health policy specific to each rare disease, it is possible to have a global rather than a piecemeal approach in the areas of scientific and biomedical research, drug research and development, industry policy, information and training, social benefits, hospitalisation and outpatient care. In the recent past, several initiatives at EU and Member States levels have been taken and proved efficient in developing suitable solutions which are now having a positive impact on the quality of life of patients. These initiatives are presented here. They include the establishment of Orphanet, a database of rare diseases and orphan drugs providing an encyclopaedia of rare diseases and a directory of associated expert services, the funding of research networks to boost the collaboration between research teams, as well as the funding of networks of clinical centres of reference to better serve the patients and contribute to developing clinical research. Bei den meisten seltenen Krankheiten handelt es sich um lebensbedrohliche und zu dauerhafter Hinfälligkeit führende Störungen; sie sind überwiegend genetisch bedingt. Ihre jeweilige Seltenheit verlangt spezielle koordinierte Anstrengungen zur Verbesserung der Diagnose, Behandlung und Prävention. Während es schwierig ist, für jede seltene Krankheit eine Strategie im Rahmen der Gesundheitsvorsorge zu treffen, so ist es doch möglich, eine globale statt eine bruchstückhafte und unsystematische Herangehensweise auf den Gebieten der biomedizinischen Forschung, Medikamentenentwicklung, Einbeziehung der Industrie, der Informationsgebung und Ausbildung, der Sozialfürsorge sowie der stationären und ambulanten Behandlung zu entwickeln. In letzter Zeit wurde von der EU und ihren Mitgliedsländern eine Reihe von Initiativen gestartet, die ihre Ef fizienz im Hinblick auf die Entwicklung von Lösungen zur Verbesserung der Lebensqualität Betroffener unter Beweis gestellt haben. Diese Initiativen werden hier vorgestellt. Sie beinhalten den Aufbau von Orphanet, einer Datenbank für seltene Krankheiten und diesbezügliche Medikamente, die eine Enzyklopädie dieser Krankheiten und Auflistungen spezieller Versorgungseinrichtungen bereitstellt, die Förderung von Netzwerken zur Verbesserung der Zusammenarbeit von Forschungseinrichtungen sowie die Förderung klinischer Referenzzentren zur Verbesserung der Patientenversorgung und klinischen Forschung.
- 19 November 2007
- Published by Springer Nature in Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
- Vol. 50 (12) , 1477-1483
Networking for rare diseases: a necessity for Europe
Most rare diseases are life-threatening and chronically debilitating conditions, and the vast majority of them are genetically determined. Their individually low prevalence requires special combined efforts to address them so as to improve diagnosis, care and prevention. Though it is difficult to develop a public health policy specific to each rare disease, it is possible to have a global rather than a piecemeal approach in the areas of scientific and biomedical research, drug research and development, industry policy, information and training, social benefits, hospitalisation and outpatient care. In the recent past, several initiatives at EU and Member States levels have been taken and proved efficient in developing suitable solutions which are now having a positive impact on the quality of life of patients. These initiatives are presented here. They include the establishment of Orphanet, a database of rare diseases and orphan drugs providing an encyclopaedia of rare diseases and a directory of associated expert services, the funding of research networks to boost the collaboration between research teams, as well as the funding of networks of clinical centres of reference to better serve the patients and contribute to developing clinical research. Bei den meisten seltenen Krankheiten handelt es sich um lebensbedrohliche und zu dauerhafter Hinfälligkeit führende Störungen; sie sind überwiegend genetisch bedingt. Ihre jeweilige Seltenheit verlangt spezielle koordinierte Anstrengungen zur Verbesserung der Diagnose, Behandlung und Prävention. Während es schwierig ist, für jede seltene Krankheit eine Strategie im Rahmen der Gesundheitsvorsorge zu treffen, so ist es doch möglich, eine globale statt eine bruchstückhafte und unsystematische Herangehensweise auf den Gebieten der biomedizinischen Forschung, Medikamentenentwicklung, Einbeziehung der Industrie, der Informationsgebung und Ausbildung, der Sozialfürsorge sowie der stationären und ambulanten Behandlung zu entwickeln. In letzter Zeit wurde von der EU und ihren Mitgliedsländern eine Reihe von Initiativen gestartet, die ihre Ef fizienz im Hinblick auf die Entwicklung von Lösungen zur Verbesserung der Lebensqualität Betroffener unter Beweis gestellt haben. Diese Initiativen werden hier vorgestellt. Sie beinhalten den Aufbau von Orphanet, einer Datenbank für seltene Krankheiten und diesbezügliche Medikamente, die eine Enzyklopädie dieser Krankheiten und Auflistungen spezieller Versorgungseinrichtungen bereitstellt, die Förderung von Netzwerken zur Verbesserung der Zusammenarbeit von Forschungseinrichtungen sowie die Förderung klinischer Referenzzentren zur Verbesserung der Patientenversorgung und klinischen Forschung.
- Open Access
- 1 March 2006
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 1 (1) , 1-2
Orphanet Journal of Rare Diseases: Launch Editorial
- 1 March 2006
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 1 (1) , 1-2
Open AccessOrphanet Journal of Rare Diseases: Launch Editorial
- Open Access
- 1 December 2003
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 11 (S2) , S13-S48
Provision of genetic services in Europe: current practices and issues
- 1 December 2003
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 11 (S2) , S13-S48
Open AccessProvision of genetic services in Europe: current practices and issues
- 1 December 2003
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 11 (S2) , S123-S142
Genetic information and testing in insurance and employment: technical, social and ethical issues
The present paper examines the professional and scientific views on the social, ethical and legal issues that impact on genetic information and testing in insurance and employment in Europe. For this purpose, many aspects have been considered, such as the concerns of medical geneticists, of the insurers and employers, of the public, as well as the regulatory frameworks and unresolved issues. The method used was primarily the review of the technical, social, economical and ethical aspects of advances in genetics and the concerns of parties who are involved, that is, the insurers, the employers and the public. The existing guidelines and legislation on this topic were also reported. Then, the method was to examine the issues debated by these parties in Europe, as well as by 47 experts from 14 European countries invited to an international workshop organized by the European Society of Human Genetics Public and Professional Policy Committee in Manchester, UK, 25–27 February 2000. The result of this was that the most important issues raised by genetic information and testing in insurance and employment in Europe include a need for clear definitions of terms used in genetics, declaring the grounds on which genetic information is or is not used, and promoting confidence between the public and the insurance industry. There is currently very little use of genetic information in relation to employment, but the situation should be kept under review.
- 1 December 2003
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 11 (S2) , S123-S142
Genetic information and testing in insurance and employment: technical, social and ethical issues
The present paper examines the professional and scientific views on the social, ethical and legal issues that impact on genetic information and testing in insurance and employment in Europe. For this purpose, many aspects have been considered, such as the concerns of medical geneticists, of the insurers and employers, of the public, as well as the regulatory frameworks and unresolved issues. The method used was primarily the review of the technical, social, economical and ethical aspects of advances in genetics and the concerns of parties who are involved, that is, the insurers, the employers and the public. The existing guidelines and legislation on this topic were also reported. Then, the method was to examine the issues debated by these parties in Europe, as well as by 47 experts from 14 European countries invited to an international workshop organized by the European Society of Human Genetics Public and Professional Policy Committee in Manchester, UK, 25–27 February 2000. The result of this was that the most important issues raised by genetic information and testing in insurance and employment in Europe include a need for clear definitions of terms used in genetics, declaring the grounds on which genetic information is or is not used, and promoting confidence between the public and the insurance industry. There is currently very little use of genetic information in relation to employment, but the situation should be kept under review.
- 1 December 2003
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 11 (S2) , S49-S87
Population genetic screening programmes: principles, techniques, practices, and policies
This paper examines the professional and scientific views on the principles, techniques, practices, and policies that impact on the population genetic screening programmes in Europe. This paper focuses on the issues surrounding potential screening programmes, which require further discussion before their introduction. It aims to increase, among the health-care professions and health policy-makers, awareness of the potential screening programmes as an issue of increasing concern to public health. The methods comprised primarily the review of the existing professional guidelines, regulatory frameworks and other documents related to population genetic screening programmes in Europe. Then, the questions that need debate, in regard to different types of genetic screening before and after birth, were examined. Screening for conditions such as cystic fibrosis, Duchenne muscular dystrophy, familial hypercholesterolemia, fragile X syndrome, hemochromatosis, and cancer susceptibility was discussed. Special issues related to genetic screening were also examined, such as informed consent, family aspects, commercialization, the players on the scene and monitoring genetic screening programmes. Afterwards, these questions were debated by 51 experts from 15 European countries during an international workshop organized by the European Society of Human Genetics Public and Professional Policy Committee in Amsterdam, The Netherlands, 19–20, November, 1999. Arguments for and against starting screening programmes have been put forward. It has been questioned whether genetic screening differs from other types of screening and testing in terms of ethical issues. The general impression on the future of genetic screening is that one wants to 'proceed with caution', with more active impetus from the side of patients' organizations and more reluctance from the policy-makers. The latter try to obviate the potential problems about the abortion and eugenics issues that might be perceived as a greater problem than it is in reality. However, it seems important to maintain a balance between a 'professional duty of care' and 'personal autonomy'.
- 1 December 2003
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 11 (S2) , S49-S87
Population genetic screening programmes: principles, techniques, practices, and policies
This paper examines the professional and scientific views on the principles, techniques, practices, and policies that impact on the population genetic screening programmes in Europe. This paper focuses on the issues surrounding potential screening programmes, which require further discussion before their introduction. It aims to increase, among the health-care professions and health policy-makers, awareness of the potential screening programmes as an issue of increasing concern to public health. The methods comprised primarily the review of the existing professional guidelines, regulatory frameworks and other documents related to population genetic screening programmes in Europe. Then, the questions that need debate, in regard to different types of genetic screening before and after birth, were examined. Screening for conditions such as cystic fibrosis, Duchenne muscular dystrophy, familial hypercholesterolemia, fragile X syndrome, hemochromatosis, and cancer susceptibility was discussed. Special issues related to genetic screening were also examined, such as informed consent, family aspects, commercialization, the players on the scene and monitoring genetic screening programmes. Afterwards, these questions were debated by 51 experts from 15 European countries during an international workshop organized by the European Society of Human Genetics Public and Professional Policy Committee in Amsterdam, The Netherlands, 19–20, November, 1999. Arguments for and against starting screening programmes have been put forward. It has been questioned whether genetic screening differs from other types of screening and testing in terms of ethical issues. The general impression on the future of genetic screening is that one wants to 'proceed with caution', with more active impetus from the side of patients' organizations and more reluctance from the policy-makers. The latter try to obviate the potential problems about the abortion and eugenics issues that might be perceived as a greater problem than it is in reality. However, it seems important to maintain a balance between a 'professional duty of care' and 'personal autonomy'.
- 1 December 2003
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 11 (S2) , S88-S122
Data storage and DNA banking for biomedical research: informed consent, confidentiality, quality issues, ownership, return of benefits. A professional perspective
The purpose of this paper is to formulate a professional and scientific view on the social, ethical, and legal issues that impact on data storage and DNA banking practices for biomedical research in Europe. Many aspects have been considered, such as the requirements for data storage and DNA banking in the public and private sectors in Europe and the issues relating to DNA banking, that is to say the consent requirements for the banking and further uses of DNA samples, their control and ownership, and the return of benefit derived from DNA exploitation to the community. The methods comprise primarily the review of the existing professional guidelines, legal frameworks and other documents related to the data storage and DNA banking practices in public and private sectors in Europe. Then, the issues related to DNA banking were examined during an international workshop organized by the European Society of Human Genetics Public and Professional Policy Committee in Paris, France, 07–08, April, 2000. A total of 50 experts from 12 European countries attended this workshop. It came out that DNA banking for medical and research purposes is indispensable. It facilitates the constitution of large collections, sharing of samples, multiple testing on the same samples, and repeating testing over the years. However, banking organization is complex, requires multiple actors, and concerns are expressed in various countries. International standardization of ethical requirements and policies with regard to DNA banking has been recommended. Such standardization would facilitate a greater protection of individuals as well as future international cooperation in biomedical research.
- 1 December 2003
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 11 (S2) , S88-S122
Data storage and DNA banking for biomedical research: informed consent, confidentiality, quality issues, ownership, return of benefits. A professional perspective
The purpose of this paper is to formulate a professional and scientific view on the social, ethical, and legal issues that impact on data storage and DNA banking practices for biomedical research in Europe. Many aspects have been considered, such as the requirements for data storage and DNA banking in the public and private sectors in Europe and the issues relating to DNA banking, that is to say the consent requirements for the banking and further uses of DNA samples, their control and ownership, and the return of benefit derived from DNA exploitation to the community. The methods comprise primarily the review of the existing professional guidelines, legal frameworks and other documents related to the data storage and DNA banking practices in public and private sectors in Europe. Then, the issues related to DNA banking were examined during an international workshop organized by the European Society of Human Genetics Public and Professional Policy Committee in Paris, France, 07–08, April, 2000. A total of 50 experts from 12 European countries attended this workshop. It came out that DNA banking for medical and research purposes is indispensable. It facilitates the constitution of large collections, sharing of samples, multiple testing on the same samples, and repeating testing over the years. However, banking organization is complex, requires multiple actors, and concerns are expressed in various countries. International standardization of ethical requirements and policies with regard to DNA banking has been recommended. Such standardization would facilitate a greater protection of individuals as well as future international cooperation in biomedical research.